On 12 August 2025, Lupin announced that it has partnered with Sandoz to market and commercialise Lupin’s biosimilar ranibizumab (referencing Genentech’s Lucentis®) across the European Union (excluding Germany), Switzerland, Norway, Canada, Australia, Hong Kong, Vietnam, and Malaysia.
Sandoz has exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it has semi-exclusive marketing rights. Lupin remains responsible for manufacturing the product and for regulatory submissions.
Lupin is one a of a number of companies with ranibizumab biosimilars. Other ranibizumab biosimilars include Samsung Bioepis’ Byooviz® (EU-approved in September 2021, FDA-approved in September 2021); Formycon’s Ranivisio® (EU-approved in August 2022); Sandoz’s Cimerli® (FDA-approved in August 2022) and STADA/Xbrane’s Ximluci® (EU-approved 9 November 2022).